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Neoadjuvant therapy is no longer an option just for locally ad-
vanced operable cancers in order to facilitate breast-conserv-
ing surgery, but also for all early breast cancers when an
indication for chemotherapy is given [1]. Pathological com-
plete response (pCR) – defined as the absence of residual inva-
sive or sometimes even in-situ cancer on breast and lymph
nodes after preoperative therapy – has been shown to predict
long-term outcome in patient-based analyses of several ran-
domised clinical trials [2–4]. Achieving pCR is important
mainly for those patients with an unfavourable initial progno-
sis, such as HER2-positive/hormone-receptor- (HR-)negative,
triple-negative breast cancer (TNBC) and some luminal-B-like
tumours. In contrast, the survival benefit of patients with pCR
was less pronounced in luminal-A-like tumours (HR-positive,
HER2-negative, grade 1–2) [2,4].
Because of the different behaviours of breast cancer sub-
types, a neoadjuvant strategy tailored on clinicopathological
criteria should be considered the optimal option (Table 1).
2. HR-positive disease
The GeparTrio trial [5] investigated a response-guided ap-
proach based on early response assessment; the treatment
was either intensified with two additional cycles in the case
of an early response, or changed to a different chemother-
apy in the case of no response. Response-guided strategy
led to a higher pCR rate in patients with HR-positive tu-
mours, without a significant improvement in disease-free
survival. These discordant results might be explained by
the established weak prognostic impact of pCR in HR-posi-
tive disease [2,4]
3. HER2-positive disease
In studies adding trastuzumab to neoadjuvant chemother-
apy, patients with HER2-positve/HR-negative tumoursachieved the highest pCR rate across subtypes [3]. Other-
wise, in the German neoadjuvant trial experience, an
increasing number of chemotherapy cycles might be related
to a higher pCR rate in patient with HER2-positive/HR-posi-
tive disease [4]. Moreover, results from the Tryphaena study
showed that six to eight cycles of a taxane-based chemo-
therapy, including either an anthracycline or carboplatin,
plus trastuzumab and pertuzumab lead to an increased
pCR rate of >60% [6].
Currently, a sequential chemotherapy approach contain-
ing anthracycline–cyclophosphamide and a taxane plus trast-
uzumab is the better choice for patients with HER2-positive
disease. The addition of pertuzumab to this sequence, or to
a taxane–carboplatin combination, could be a future option
when it becomes available.
4. TNBC
The simultaneous application of docetaxel, doxorubicin and
cyclophosphamide (TAC) for six cycles accounts for the high-
est pCR rates in TNBC patients in the German neoadjuvant
studies, particularly for patients with an early response after
only two cycles [7].
As shown in the GeparQuinto study, the treatment effect
might be further improved by adding bevacizumab to neoad-
juvant chemotherapy [8]. However, even considering the non-
confirmatory results of the NSABP B40 trial [9], the use of this
anti-angiogenic drug in the neoadjuvant setting should be
further investigated.
In the near future the role of bevacizumab and carboplatin
will be better defined by the GeparSixto study [10] which is
investigating bevacizumab given simultaneously to weekly
carboplatin, paclitaxel, and pegylated doxorubicin in TNBC
and HER2-positive patients; and by the CALGB 40603 study
[11] which is evaluating three weekly carboplatin and bev-
acizumab in a 2 by 2 factorial design in patients treated with
weekly paclitaxel followed by dose-dense doxorubicin/
cyclophosphamide.
Table 1 – Different neoadjuvant approaches according to breast cancer subtypes.
Subtype Neoadjuvant treatment Reference
HR-positive disease EC–Pw Meta-analyses of several neoadjuvant studies2–4
TAC · 2! response-guided chemotherapy GeparTrio5
HER2-positive disease EC(H)–TH Meta-analyses of several neoadjuvant studies2–4
FECHP–TH or TCH (plus P if available) Tryphaena6
TNBC TAC Meta-analysis of seven German neoadjuvant studies7
EC–Pw Meta-analyses of several neoadjuvant studies [2–4]
Role of bevacizumab is uncertain GeparQuinto8 and NSABP 409Waiting for GeparSixto10
and CALGB 4060311
Role of carboplatin is uncertain Waiting for GeparSixto10 and CALGB 4060311
E, epirubicin; C, cyclophosphamide; Pw, paclitaxel weekly; T, docetaxel; A, doxorubicin; F, 5-fluorouracil; H, trastuzumab; P, pertuzumab; TNBC,
triple-negative breast cancer.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 8 4 –2 8 5 2855. Conclusion
In conclusion, considering that HER2-positive/HR-negative
and TNBC patients who achieve pCR showed a prognosis
comparable to that of patients with luminal-A-like tumours
[2], a neoadjuvant strategy tailored to different breast cancer
subtypes can completely change the natural history of some
cancers.
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